US Food and Drug Administration (USFDA) has concluded inspection of Marksans Pharma’s Goa facility. The inspection of the facility took place between February 25 to March 6, 2019, resulting in a Form 483 with eight observations. None of these observations are considered either critical or repetitive in nature.
The company is highly confident of closing these expeditiously and remains committed to global standards of quality & compliance. The site will continue to supply to the US markets all approved ANDA's. This inspection will help company to received pending ANDA's approval already filed by it.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
